TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06809114: FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors

Sponsor: Axcynsis Therapeutics Pte Ltd · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 83 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06809114 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06809114 Rescue Dossier →